Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Epigenomics Studies in Acute Myeloid Leukemia disease progression

ABSTRACT: Epigenomics Studies in Acute Myeloid Leukemia disease progression

PROVIDER: PRJNA326264 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Epigenomics Studies in Acute Myeloid Leukemia disease progression [RNAseq]

Project description:We report the DNA methylation and transcriptional molecular features of paired diagnosis and relapsed Acute Myeloid Leukemia samples

2016-06-21 | GSE83533 | GEO

Epigenomics Studies in Acute Myeloid Leukemia disease progression [enhanced RRBS-seq]

Project description:We report the DNA methylation and transcriptional molecular features of paired diagnosis and relapsed Acute Myeloid Leukemia samples

2016-06-21 | GSE83532 | GEO

Epigenomics Studies in Acute Myeloid Leukemia disease progression

Project description:This SuperSeries is composed of the SubSeries listed below.

2016-06-21 | GSE83534 | GEO

Epigenetic studies in Acute Myeloid Leukemia

Project description:Epigenetic studies in Acute Myeloid Leukemia

| PRJNA301478 | ENA

Epigenomics studies in Acute Myeloid Leukemia (AML)

Project description:<p>Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through interrogation of patient samples collected through an international collaboration which assembled 138 paired (diagnosis and relapse) patient specimens.</p> <p>It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.</p>

| phs001027 | dbGaP

Dietary methionine starvation impairs acute myeloid leukemia progression

Project description:Dietary methionine starvation impairs acute myeloid leukemia progression

| PRJNA909277 | ENA

Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells

Project description:Acute myeloid leukemia (AML) is a hematologic malignancy for which several epigenetic regulators have been identified as therapeutic targets. Here we report the development of cereblon-dependent degraders of IKZF2 and casein kinase 1 alpha (CK1α) termed DEG-35 and DEG-77. We utilized a structure-guided approach to develop DEG-35 as a nanomolar degrader of IKZF2, a hematopoietic specific transcription factor that contributes to myeloid leukemogenesis. DEG-35 possesses additional substrate specificity for the therapeutically relevant target CK1α which was identified through unbiased proteomics and a PRISM screen assay. Degradation of IKZF2 and CK1α blocks cell growth and induces myeloid differentiation in AML cell lines through CK1α–p53- and IKZF2-dependent pathways. Target degradation by DEG-35 or the analog DEG-77 delays leukemia progression in murine and human AML mice models. Overall, we provide a strategy for multi-targeted degradation of IKZF2/CK1α to enhance efficacy against AML that may be expanded to additional targets and indications.

2023-03-08 | PXD039474 | Pride

Proteogenomic analysis of relapsed acute myeloid leukemia in adults and children

Project description:Despite improvement of current treatment strategies and novel targeted drugs, relapse and treatment resistance determine the major cause of death for acute myeloid leukemia (AML) patients. To identify the underlying molecular characteristics, numerous studies have been aimed to decipher the genomic- and transcriptomic landscape of AML. Nevertheless, further molecular changes allowing malignant cells to escape treatment are yet to be elucidated. Mass spectrometry is a powerful tool enabling detailed insights into proteomic changes that could explain AML relapse and resistance. Here, we investigated AML samples from 47 adult and 22 pediatric patients at serial time-points during disease progression using high resolution isoelectric focusing liquid chromatography mass spectrometry. We show that the proteomic profile at relapse is enriched for mitochondrial ribosomal proteins and subunits of the respiratory chain complex, indicative of reprogrammed energy metabolism from diagnosis to relapse. Further, higher levels of granzymes and lower levels of the anti-inflammatory protein CR1/CD35 suggest an inflammatory signature promoting disease progression. Finally, through a proteogenomic approach, we detected novel peptides, which present a promising repertoire in the search for biomarkers and tumor-specific druggable targets. Altogether, this study highlights the importance of proteomic studies in holistic approaches to improve treatment and survival of AML patients.

2023-01-09 | PXD031107 | Pride

Trib1 promotes acute myeloid leukemia progression by modulating transcriptional programs of Hoxa9

Project description:Trib1 promotes acute myeloid leukemia progression by modulating transcriptional programs of Hoxa9

| PRJNA589270 | ENA

Adhesion GPCR ADGRE2 maintains proteostasis to promote progression in acute myeloid leukemia

Project description:Adhesion GPCR ADGRE2 maintains proteostasis to promote progression in acute myeloid leukemia

| PRJNA1087687 | ENA